The human microbiome: an emerging paradigm for better health

doi:10.15406/moji.2018.06.00192

MOJ

eISSN: 2373-4442

Immunology

Editorial Volume 6 Issue 2

The human microbiome: an emerging paradigm for better health

Joseph F Murphy

Verify Captcha

Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.

Director of Immunology Applications, Caprion Biosciences Inc, Canada

Correspondence: Joseph F Murphy, Director of Immunology Applications, Caprion Biosciences Inc, 201 President Kennedy Avenue, Canada,, Tel 205-500-8990

Received: January 01, 1971 | Published: April 19, 2018

Citation: Murphy JF. The human microbiome: an emerging paradigm for better health. MOJ Immunol. 2018;6(2):54-55 DOI: 10.15406/moji.2018.06.00192

Download PDF

Abstract

The human microbiome is rapidly emerging as an intriguing field of scientific research. Its role in human physiology and modulation of human diseases spanning genetic expression, immune system, and mental health to body weight is currently the focus of intense investigation. Dysbiosis, the alteration of the bacterial ecology, is being linked to increasing illnesses. Although still in its infancy, investigating the human microbiome is becoming an exciting field of scientific endeavor that addresses the symbiotic relationship between humans and their internal microbiome. This research is revealing a vast reservoir of knowledge that will ultimately have enormous implications for the treatment of diseases.

Introduction

The past few years has witnessed a blossoming of research revolving around the human microbiome. Increased knowledge about this field has led to realizing its crucial role in modulating human health. The microbiome genome, compromised of bacteria, fungi, viruses, and protozoa is referred to as our second genome. It is estimated that there are 100 trillion microbes, comprised of over 1,000 species. The composition varies from person to person based on several factors, such as diet, health history, geographic location, and ancestry. They are intertwined with our immune system, interacting directly with our body’s natural killer T-cells. Moreover, this complex ecosystem must be properly balanced and nurtured to remain healthy. Imbalances within our microbiome can lead to illness. Our microbiome also helps control gene expression, which ultimately affects several facets of our physiology.

Gut instinct

The human enteric nervous system (ENS), an off shoot of the autonomic nervous system, is embedded in the wall of our intestines, and works both independently and in alignment with the brain. Comprised of an estimated 500 million neurons, it is also the original nervous system, emerging in the first vertebrates and becoming more complex as vertebrates evolved. Our ENS is believed to be largely responsible for our “gut instinct,” responding to environmental threats and sending information to our brain that ultimately affects our well-being. Like the brain, the ENS uses more than 30 neurotransmitters, with over 90% of the body's serotonin found in the gut. Since our microbiome is closely linked to our autonomic nervous system, it follows that microbe-based therapeutics can lead to long-lasting effects and can be readily modified for regulatory aspects. For example, if a pathogen crosses the gut lining, immune cells in the gut wall secrete inflammatory substances that are detected by neurons in the ENS. The importance of the microbiota in influencing mental health extends beyond mood swings, but also includes the development of serious conditions, such as autism, Alzheimer’s disease, and schizophrenia.

Inflammation

Given that over 70% of the body’s immune system is committed to maintaining homeostasis with the human microbiome, it stands to reason that the gut microbiota is an important regulator of immune responses. It has been established that the microbiome plays a protective role in acute local inflammatory responses to injury partly through toll-like receptor (TLR) activation promoting survival and tissue repair. Inability to regulate these responses contributes to the development of food allergies and various inflammatory bowel diseases, while immunity and inflammation within organs distal from the intestine are affected by microbial composition and density.¹ For a comprehensive analysis of the potential mechanisms underlying microbiota-based changes to systemic inflammatory disease, see review by Clemente et al.²

Cancer and immuno-oncology

It is well established that the clinical response to checkpoint inhibitors varies among patients. There is accumulating evidence that this variance may be mediated through the gut microbiome. Several studies have demonstrated that the response or inactivity of cancer patients to immunotherapy is dependent on the intestinal flora. Animal models have demonstrated that T-cell infiltration into the tumor microenvironment, which promotes tumor regression, can be modified by restoring a healthy intestinal microbiome. Moreover, the efficacy of checkpoint inhibitors is enhanced by the intestinal microbiome.³ Cancer immunotherapy efficacy with immune checkpoint antibodies can be diminished by antibiotics, while better efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will probably rely on therapeutic tools, in conjunction with companion diagnostics, to identify and correct defects in the microbiome that diminish therapeutic efficacy.⁴

Conclusion

As the field evolves, we are beginning to elucidate the mechanisms underpinning the symbiotic relationship between human physiology and the microbiome. An understanding of this complex relationship will allow us to prevent or intervene effectively in many diseases. One of the most important questions is to address the gaps to move beyond correlation to causation of human diseases. Pivotal to this quest will be deciding upon the technological tools required (in vitro, ex vivo, and in vivo models, in addition to computational or “omic” tools) to gain a mechanistic understanding of precisely how the functional microbiome engages with the immune system. Can the microbiome be used to predict treatment response, or as a cancer biomarker? Using a metaproteomic approach, coupled with 16S rRNA sequencing analysis, Caprion is actively looking at these questions to help companies working in this field address them. Insight into the landscape of microbiome-based therapy will be instrumental in providing therapeutic strategies for several disease states, including cancer immunotherapy.